Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow?
Circulating tumor DNA currently functions mainly as a prognostic and response-associated biomarker in lung cancer immunotherapy, while its predictive, decision-defining role remains an important but investigational objective.